Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Journal of Clinical Medicine|September 13, 2025
Clinical Predictive Factors for the Development of Short Bowel Syndrome in a Cohort of Patients with Crohn's Disease: A Prospective StudyLaura Parisio, Angelo Del Gaudio, Jacopo Iaccarino, et al.
Frontiers in Gastroenterology (Lausanne, Switzerland)|March 13, 2026
Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s updateLetizia Masi, Cristina Ciuffini, Valentina Petito, et al.
Biomedicines|April 23, 2022
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control StudyAlfredo Papa, Franco Scaldaferri, Marcello Covino, et al.
Alimentary Pharmacology & Therapeutics|July 25, 2022
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Federica Crispino, et al.
Journal of Personalized Medicine|June 24, 2022
Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot StudyCristina Graziani, Lucrezia Laterza, Claudia Talocco, et al.
United European Gastroenterology Journal|November 18, 2020
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD studyDaniela Pugliese, Giuseppe Privitera, Francesca Rogai, et al.
United European Gastroenterology Journal|March 15, 2025
European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN: Part 2: Screening, Special Populations, Nutritional Goals, Supportive Care, Primary Care PerspectiveMarco Vincenzo Lenti, Heinz Florian Hammer, Ilja Tacheci, et al.
United European Gastroenterology Journal|March 25, 2025
European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN. Part 1: Definitions, Clinical Phenotypes, and Diagnostic Testing for MalabsorptionMarco Vincenzo Lenti, Heinz Florian Hammer, Ilja Tacheci, et al.
Advances in Therapy|June 30, 2026
Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE StudyGiuseppe Privitera, Flavia Palumbo, Fabio Salvatore Macaluso, et al.
Inflammatory Bowel Diseases|February 11, 2025
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus ConferenceLoris R Lopetuso, Sara Deleu, Pierluigi Puca, et al.
Pageof 8